Study Highlights Potential of Psilocybin for Veterans with Depression
A recent study focusing on U.S. military veterans suffering from severe treatment-resistant depression suggests that a single dose of psilocybin could lead to significant improvements in depressive symptoms for up to 12 months. Interestingly, six months after receiving the dose, half of the participants reported being in remission, while 80% experienced a notable reduction in symptoms. However, the benefits seemed to decline around the nine-month mark. This research was published in the Journal of Affective Disorders.
Depression is a complex mental health disorder that manifests through persistent sadness, a loss of interest in activities, low energy levels, and challenges with daily functioning. Its toll can greatly affect mood, thinking, and overall physical health—hence, standard treatments have included antidepressants, psychotherapy, or a mix of both.
Yet, not everyone finds solace in these treatments. When someone does not see improvement after trying at least two different antidepressants, their condition is often labeled as treatment-resistant depression (TRD). Those grappling with TRD usually deal with more severe and prolonged depressive episodes, which can significantly impact their daily lives.
Mental health professionals frequently explore various strategies for TRD, which might include changing medications or combining them with other drugs—like mood stabilizers or antipsychotics. Still, these alternatives sometimes offer limited relief, leading researchers to investigate potentially more effective treatments, such as psilocybin.
According to study author Sara Ellis and her team, while previous research has indicated short-term benefits of psilocybin in treating depression, fewer studies have examined the duration of those effects. Thus, this study aimed to monitor changes in depressive symptoms over a year following a single psilocybin dose in military veterans.
Psilocybin, a naturally occurring psychedelic found in certain mushrooms commonly termed “magic mushrooms,” is under investigation for its effectiveness in addressing various issues like depression, anxiety, PTSD, and addiction. Evidence indicates that in a controlled environment with proper psychological support, psilocybin may lead to swift and lasting health improvements. However, it can also produce negative side effects, including distressing hallucinations and nausea, and remains a controlled substance in numerous regions.
In this pilot study, researchers tracked 10 military veterans diagnosed with severe TRD. Although the sample was small, veterans are notably at a higher risk for persistent depression, particularly forms resistant to treatment, making the findings pertinent.
Prior to dosing, participants engaged in a couple of preparatory therapy sessions. On the day of dosing, each veteran received a single 25 mg capsule of psilocybin at Stanford University School of Medicine, during sessions that lasted from 6 to 8 hours with two licensed therapists present. After the initial dose, their vital signs were monitored, and they participated in additional integration sessions over the following weeks.
Assessments for depressive symptoms, anxiety, and functional impairment took place multiple times in the year following the treatment. The tools used included established rating scales. Participants also filled out a scale designed to evaluate their psychedelic experience, and safety was carefully monitored throughout the process.
Results revealed a notable reduction in depression scores at all assessment points. By the six-month mark, 50% of participants met the remission criteria, meaning their symptoms were either minimal or completely absent, and 80% recorded a meaningful reduction in symptoms.
That said, the antidepressant effects appeared to diminish after six months. By the 12-month follow-up, 40% of participants still met the response criteria, and 30% were still in remission. While scores were better than at three or twelve weeks post-treatment, they remained significantly lower than baseline levels.
“This first-of-a-kind study on the long-term effects of psilocybin for veterans with severe TRD showcased significant sustained reductions in depression scores for up to 12 months. However, the benefits began to wane around the six-month point and became more pronounced after nine months,” the authors noted, emphasizing the need for further research.
This study adds to the growing body of evidence suggesting that psilocybin could provide long-term advantages for depression, particularly for those who haven’t found relief with standard treatments. Yet, there are significant limitations; notably, the absence of a control group and the fact that participants knew they were receiving psilocybin—which might influence outcomes through expectancy effects or the Hawthorne effect, where people modify their behavior when they know they are being observed.
Without a control condition, it’s tricky to ascertain how much of the observed improvements can be credited to psilocybin versus psychological support, natural symptom variations, or other factors. The small sample size further complicates any broad conclusions.
The paper titled “Long-term outcomes of single-dose psilocybin for U.S. military Veterans with severe treatment-resistant depression – 12-month data from an open-label pilot study” was authored by a team including Sara Ellis, Catherine Bostian, and others.
